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Abstract
Introduction: Intensive care unit (ICU) patients are predisposed to thromboembolism. Routine prophylactic
anticoagulation is widely recommended. Low-molecular-weight heparins, such as enoxaparin, are increasingly used
because of predictable pharmacokinetics. This study aims to determine the subcutaneous (SC) dose of enoxaparin
that would give the best anti-factor Xa levels in ICU patients.
Methods: The 72 patients admitted to a mixed ICU at Odense University Hospital (OUH) in Denmark were
randomised into four groups to receive 40, 50, 60, or 70 mg SC enoxaparin for a period of 24 hours. Anti-factor Xa
activity (aFXa) was measured before, and at 4, 12, and 24 hours after administration. An AFXa level between 0.1 to
0.3 IU/ml was considered evidence of effective antithrombotic activity.
Results: Median peak (4 hours after administration), aFXa levels increased significantly with an increase in
enoxaparin dose, from 0.13 IU/ml at 40 mg, to 0.14 IU/ml at 50 mg, 0.27 IU/ml at 60 mg, and 0.29 IU/ml at 70 mg
(P = 0.002). At 12 hours after administration, median aFXa levels were still within therapeutic range for those
patients who received 60 mg (P = 0.02).
Conclusions: Our study confirmed that a standard dose of 40 mg enoxaparin yielded subtherapeutic levels of
aFXa in critically ill patients. Higher doses resulted in better peak aFXa levels, with a ceiling effect observed at
60 mg. The present study seems to suggest inadequate dosage as one of the possible mechanisms for the higher
failure rate of enoxaparin in ICU patients.
Trial Registration: ISRCTN03037804
Introduction
Geerts et al. [1] determined the prevalence of deep vein
thrombosis (DVT) in intensive care unit (ICU) patients
not receiving prophylaxis to be in the range of 10-80%.
The critically ill patient is especially predisposed to
thromboembolism, possessing many inherent risk fac-
tors: cardiac failure, trauma, sepsis, cancer, increasing
age, and obesity [1-5]. The acquisition of others, for
example: respiratory support with decreased mobility
and invasive monitoring, further tips the scale in favor
of thrombosis during the ICU stay. Thus, these patients
should undergo routine assessment for venous throm-
boembolism (VTE). The use of routine thromboprophy-
laxis will probably be justified in most [1,2].
Discerning DVT in critically ill patients is difficult [6].
The history and physical examination are often of little
use, and thus, these patients are vulnerable to a delay in
diagnosis. Low-molecular-weight heparins (LMWHs) are
often used as a safe and effective means of prophylaxis
[7-9] against VTE in medical and surgical patients.
However, the efficacy of LMWHs in critically ill patients
is less certain [10].
The antithrombotic activity of LMWHs is often deter-
mined by aFXa assay, despite several studies finding no
direct correlation between aFXa activity and clinical out-
come. Mayr [11] concluded that the European standard
daily dose of 40 mg enoxaparin [12] was ineffective in
ICU patients to achieve the recommended, albeit unpro-
ven, aFXa levels of 0.1 to 0.3 IU/ml. Thus, existing
guidelines in other patient populations should not be
directly applied to critical care patients without further
study [2].* Correspondence: sianrob@msn.com1Department of Anaesthesia and Intensive Care, Odense University Hospital
(OUH), Sdr. Boulevard 29. Odense C, DK 5000, Denmark
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Most intensive care physicians widely acknowledge the
need for evidence-based guidelines for antithromboem-
bolic prophylaxis in this patient population and lament
the dearth of research on VTE in critical care patients
[4]. This study aims to establish the optimal dose of
enoxaparin for ICU patients.
Materials and methods
Study population
The sample population consisted of 72 consecutive
patients admitted to the ICU who were ≥ 18 years of
age, with a minimum stay of >24 hours. Patients weigh-
ing <50 kg or >90 kg were excluded. Likewise, patients
with bleeding diathesis, those in need of an operation
within the time frame of the study, pregnant patients,
and patients requiring continuous veno-venous hemofil-
tration were deemed ineligible. We recorded patient
demographics such as age, sex, weight, height, and body
mass index (BMI). The diagnosis on admission was also
noted, and patients were classified according to standard
ICU severity-of-illness scoring systems (APACHE II,
Acute Physiology and Chronic Health Evaluation, and
SAPS II, Simplified Acute Physiology Score) on the day
of entry into the study.
Study design
A prospective randomised double-blinded study was
conducted at an 18-bed tertiary medicosurgical ICU.
The patients were randomized into four groups/arms by
sequentially numbered, sealed envelopes to receive one
of the following SC doses of enoxaparin: 40, 50, 60, or
70 mg for a period of 24 hours. Patients, investigators,
and all other personnel involved in the conduct of the
study were blinded to individual treatment assignments.
Attending physicians received envelopes with the
assigned doses, which they then prescribed. The test
doses were dispensed by the nurses. Attending physi-
cians and nurses were therefore not blinded.
On the day of the study, blood samples were drawn
from indwelling catheters immediately before, and at 4,
12, and 24 hours after the administration of enoxaparin
to determine anti-factor Xa (aFXa) activity, antithrombin
(AT), prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), thrombin-antithrombin complexes
(TAT), fibrinogen, platelets, and D-dimer. Serum creati-
nine, as well as creatinine clearance, was determined for
each patient. Patients were considered nonresponders if
they showed no change in anti-factor Xa levels from
baseline after administration of enoxaparin.
The study was performed in accordance with ethical
principles set forth in the Declaration of Helsinki and
with local regulations. The Committee for Good Clinical
Practice at OUH approved and monitored the study.
Written informed consent was obtained from each
patient where possible, or otherwise from the closest
family member.
The funding sources for this research had no role in
the design, data collection, analysis, interpretation, or
reporting of this study.
Medication
Enoxaparin (Klexane; Sanofi-Aventis Denmark A/S,
Hørsholm, Denmark) was available as prefilled single-
dose syringes containing 20 mg and 40 mg. Nurses were
instructed to titrate the dosage carefully to avoid
inaccuracies.
Assay methods
Samples for aFXa activity of heparin in plasma and TAT
were stored at -80°C before analysis, whereas samples
for all other hemostatic parameters were analyzed within
2 hours of collection. The frozen plasma samples were
thawed and assayed in batches. Levels of aFXa activity
were determined by using a validated chromogenic assay
kit (COAMATIC Heparin; Chromogenix, Instrumenta-
tion Laboratory Company, Lexington, KE, USA) with
the substrate S-2732, and the apparatus (STA-R Evolu-
tion; Diagnostica Stago, Asnières, France). The TAT
complexes were determined by using an enzyme-immu-
noassay (Enzygnost TAT micro; Siemens, Marburg,
Germany).
Outcome measures
The primary end point was peak anti-factor Xa levels.
Secondary outcomes included AT, PT, aPTT, TAT,
fibrinogen, platelets, and D-dimer.
Statistical analysis
We calculated that 80 patients would be needed to detect
an absolute difference of 30% in anti-factor Xa levels 4
hours after enoxaparin administration between the groups,
assuming a power of 80% and a significance level of 5%.
Statistical tests were two-sided and performed by using a
significance level of 5%. A database was maintained in
Microsoft Excel. The ICU patients were enrolled in the
study between February 2006 and March 2009. The Con-
sort diagram [13] shows patient disposition. (Figure 1).
Patient characteristics
Thirty-two patients were admitted with pneumonia,
exacerbation of chronic obstructive pulmonary disease
(COPD), or other respiratory complaints. The next largest
medical patient group, comprising 15 patients, consisted
entirely of septic patients with or without the presence of
shock. Among the surgical patients were nine admitted
with ileus or other intestinal complaints, five with pancrea-
titis or infections in the biliary tree, and five with multiple
trauma. At baseline, age, APACHE II score, BMI, and
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creatinine clearance did not differ significantly between
the control group (the group receiving 40 mg enoxaparin),
and the three test groups. SAPS II scores, however, were
significantly lower in the group receiving 70 mg enoxa-
parin. All demographic data have been tabulated (Table 1).
Primary results
A strong positive correlation was found between the
dose of enoxaparin and aFXa activity levels. Median
peak (4 hours after administration) aFXa levels increased
significantly with an increase in enoxaparin dose, from
0.13 IU/ml at 40 mg, to 0.14 IU/ml at 50 mg, 0.27 IU/
ml at 60 mg, and 0.29 IU/ml at 70 mg (P = 0.002).
The group receiving 40 mg had the highest number
of non-responders (n = 5). The group receiving 70 mg
had the highest number of patients with aFXa levels
>0.3 IU/ml (n = 7). There was some variability in anti-
factor Xa levels within the same dose group. For a
dose of 40 mg enoxaparin, subtherapeutic levels
occurred in 28% at 4 hours, 67% at 12 hours, and 83%
at 24 hours. For a dose of 60 mg enoxaparin, subthera-
peutic levels occurred in 5% at 4 hours, 30% at 12
hours, and 90% at 24 hours. At 12 hours after admin-
istration, median aFXa levels were still within therapeu-
tic range for patients who received 60 mg (P = 0.02)
(Figures 2 and 3).
Secondary results
No significant difference was found in the PT, aPTT,
AT, platelet count, fibrinogen, TAT complexes, or
Table 1 Clinical characteristics of the study population
Enoxaparin dose 40 mg
(n = 18)
50 mg
(n = 16)
60 mg
(n = 20)
70 mg
(n = 18)
p
Gender (m:f) 11:7 8:8 12:8 11:7 0.9
Age (years) 63 (57-71) 65 (55-75) 63 (55-70) 70 (46-74) 0.9
BMI (kg/m2) 26 (24-28) 24 (21-27) 26 (23-27) 25 (22-29) 0.5
SAPS II 37 (26-40) 38 (29-51) 38 (30-43) 29 (21-35) 0.04*
APACHE II 12 (9-15) 16 (11-19) 13 (9-15) 8 (6-15) 0.1
Medical:Surgical 13:5 11:5 16:4 11:7
Creatinine clearance (ml/min) 82 (48-104) 58 (36-103) 65 (40-114) 57 (40-119) 0.8
BMI, Body Mass Index; SAPS II, Simplified Acute Physiology Score II; APACHE II, Acute Physiology and Chronic Health Evaluation. Data are expressed as median
(25-75 percentiles) or number.
Figure 1 Consort diagram.
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D-dimer levels between the four groups. No significant
change from baseline was noted in these coagulation
parameters within each group over the 24-hour study
period (Table 2). We conducted a multiple regression
analysis to determine whether creatinine clearance,
BMI, age, or organ-failure scores had any influence on
the levels of anti-factor Xa. No such influence was
found.
Adverse events
One minor nosebleed occurred in a patient with low plate-
let count (<65 × 109/L) given 50 mg enoxaparin. A single
Figure 3 Variation in anti-factor Xa over time for each dose of enoxaparin. AFXa denotes anti-factor Xa.
Figure 2 Scatter diagram depicting anti-factor Xa levels for each dose, 4 hours after enoxaparin administration. AFXa denotes anti-
factor Xa.
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death occurred in each of the 40 mg, 50 mg, and 60 mg
groups. These patients did not die with/of bleeding.
Discussion
Effectivity of enoxaparin is measured by aFXa activity.
Peak concentration of aFXa activity occurs at 3 to 4
hours after SC enoxaparin injection [12,14]. AFXa activ-
ity levels between 0.1 and 0.3 IU/ml are considered to
represent effective antithrombotic activity [11,15].
European standard dose of 40 mg enoxaparin SC,
once daily, is often used as VTE prophylaxis in critical
care patients [12]. Priglinger and Mayr et al. [10,11]
demonstrated low effectiveness of this standard in
achieving the recommended anticoagulant aFXa levels.
This study concurs with the finding that 40 mg yielded
subtherapeutic levels of aFXa in critically ill patients.
The reasons for this apparent heparin resistance/failure
are intriguing, and not entirely clear. Some authors sug-
gest that physiologic mechanisms, or pharmacologic
agents, for example, vasopressors, impair absorption of
SC heparin through adrenergic-mediated vasoconstric-
tion of peripheral blood vessels [11,14,16,17]. Others
theorized that the presence of SC edema may decrease
heparin absorption. However, no differences in aFXa
activity after SC injection of 2,500 IU dalteparin for
VTE prophylaxis between ICU patients with and with-
out edema have been found [18]. Still others maintain
that the presence of multiple organ dysfunction in ICU
patients may alter drug metabolism, distribution, and
binding to albumin and acute-phase proteins [11].
We included 80 patients in the trial (the same number
of patients as the trial conducted by Mayr et al.); eight
were transferred before they could participate. The
remaining 72 patients were randomized and treated
according to the intent-to-treat principle. We found a
positive correlation between the dose of enoxaparin and
aFXa levels ≤ 60 mg. Some variability in anti-factor Xa
levels was found within the same dose group, suggesting
a wide dispersion around the mean. In the study of
Mayr et al. [11], ICU patients received 40 mg enoxa-
parin. Subsequent aFXa concentrations were below the
therapeutic level in 27% of patients at 4 hours, 58% at
12 hours, and 88% at 24 hours. Those results reflect the
findings in our study, in which, for those patients who
received 40 mg enoxaparin, subtherapeutic levels
occurred in 28% at 4 hours, 67% at 12 hours, and 83%
at 24 hours. For a dose of 60 mg enoxaparin, subthera-
peutic levels occurred in 5% at 4 hours, 30% at 12
hours, and 90% at 24 hours. A ceiling effect was
observed at 60 mg, above which the potential for bleed-
ing complications was introduced. Further clinical trials
using 60 mg daily, with clinical end points, are needed.
No significant change from baseline occurred in aPTT,
PT, AT, platelet count, D-dimer, and fibrinogen levels,
irrespective of the dose of enoxaparin. These findings
are consistent with other studies, which found no
change in these hemostatic parameters with LMWH use
[10,11]. TAT serves as an indicator of thrombin produc-
tion and reflects the activation of coagulation. As enoxa-
parin moderates the conversion of prothrombin to
thrombin, TAT levels might be expected to decrease
with enoxaparin use [19,20]. In our study, a nonsignifi-
cant trend toward decreased TAT levels with increasing
dose of enoxaparin was observed.
Mayr et al. [11] showed a significant negative correla-
tion between aFXa levels and multiple organ dysfunc-
tion. Judging from the APACHE II score, the study
patients all appear to be moderately to severely ill. The
finding that patients who received 70 mg had lower
SAPS II scores was unexpected, as the study was rando-
mized; however, comparison of multiple parameters will
invariably lead to one such parameter attaining signifi-
cance purely by chance.
Periodic monitoring of aFXa levels is recommended in
special populations (for example, in pregnant patients,
children, patients with acute kidney injury (AKI), or in
those at extremes of body weight [21]. The aFXa activity
3 hours after enoxaparin had a negative correlation with
BMI [10], owing to reduced blood flow in fat tissues,
resulting in decreased drug absorption [11], and thus
obese patients were not included. Standard therapeutic-
dose enoxaparin in patients with severe AKI led to
Table 2 Other coagulation parameters at baseline
Parameter Enoxaparin
40 mg
Enoxaparin
50 mg
Enoxaparin
60 mg
Enoxaparin
70 mg
p
TAT (μg/L) 8 (6-16) 10 (5-15) 13 (7-25) 11 (6-19) 0.5
aPTT (seconds) 41 (36-49) 44 (36-47) 40 (37-46) 43 (39-49) 0.9
PT (%) 73 (43-81) 73 (56-82) 60 (54-88) 67 (52-77) 1.0
Platelets (×109/L) 211 (147-356) 220 (165-278) 201 (137-283) 299 (200-394) 0.4
AT (%) 77 (48-99) 72 (40-109) 72 (45-105) 82 (65-99) 0.9
Fibrinogen (μmol/L) 15 (13-18) 16 (12-18) 16 (13-19) 15 (11-21) 1.0
Ddimer (mg/L) 2 (2-5) 4 (2-5) 3 (2-4) 3 (2-5) 0.5
Data are expressed as median (25th-75th percentiles) or number.
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accumulation, resulting in higher aFXa levels and a con-
current increased risk of bleeding complications [21,22].
Many advocate avoiding the use of LMWHs or using a
lower dose of these agents combined with careful moni-
toring of drug levels and anticoagulant effects [1,23].
From the median creatinine clearance in Table 1, it is
easily inferred that study patients had renal functions
that ranged from being normal to only moderately
impaired. This was done to prevent AKI from influencing
the anticoagulant effect of the different enoxaparin doses.
One clear limitation of our study was that it was not
designed to detect VTE. The patients had a drug expo-
sure of only 24 hours and were not screened for VTE
by using Doppler ultrasound. In addition, the nurses
found it somewhat difficult to titrate such small doses
of enoxaparin, and this may have resulted in the varia-
bility in anti-factor Xa levels seen within the same
dose group. Despite this, the present study is both
timely and relevant to issues facing intensive care phy-
sicians. The inclusion of 72 patients is quite good for a
project of this nature, and the study was powered to
80%. In addition, our study generates the hypothesis of
inadequate dosage being one of the possible mechan-
isms for the higher failure rate of enoxaparin in ICU
patients.
Our findings cannot be extrapolated to mean that ICU
patients receiving 60 mg are better protected than are
those receiving a standard dose of 40 mg, as aFXa activ-
ity is only a surrogate parameter.
Most studies suggest that although aFXa activity can-
not be directly related to clinical outcome [7,20,24,25],
lower concentrations seem to result in less-effective pre-
vention of VTE. One study has even demonstrated a sta-
tistically significant relation between aFXa levels and
wound hematoma and thrombosis, with regression ana-
lysis suggesting that aFXa levels are predictive of out-
come [15]. It remains to be established whether these
results obtained with enoxaparin can be generalized to
other LMWHs.
Conclusions
Our study confirms that the standard dose of 40 mg
enoxaparin yielded subtherapeutic levels of aFXa in cri-
tically ill patients. In the present study, 60 mg, or 1.5
times the standard dose, resulted in the best peak aFXa
levels. The study seems to suggest inadequate dosage as
one of the possible mechanisms for the higher failure
rate of enoxaparin in ICU patients. Further trials using
60 mg daily, with clinical end points, are needed.
Key messages
• The present study seems to suggest inadequate
dosage as one of the possible mechanisms for the
high failure rate of enoxaparin in ICU patients.
• 60 mg, or 1.5 times the standard dose, resulted in
the best peak aFXa levels.
• Further trials using 60 mg daily, with clinical end
points, are needed.
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